Study Evaluating Approach to Treatment of Haemophilia A and B in Spain

NCT00581438

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hemophilia A, Hemophilia B
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Haemophilia A or B patients of any age

- Written informed consent

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hemophilia A, Hemophilia BStudy of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B
NCT03938792
  1. Frankfurt am Main,
  2. Muscat,
  3. Istanbul,
  4. Little Rock, Arkansas
  5. Tampa, Florida
  6. New Hyde Park, New York
  7. Pleven,
  8. Sofia,
  9. Hong Kong,
  10. Hong Kong,
  11. Surat, Gujarat
  12. Pune, Maharashtra
  13. Pune, Maharashtra
  14. Nagoya, Aichi
  15. Kashihara, Nara
  16. Fuchu, Tokyo
  17. Setagaya-ku, Tokyo
  18. Hiroshima,
  19. Daegu,
  20. Seoul,
  21. Seoul,
  22. Samara,
  23. Belgrade,
  24. Belgrade,
  25. Kragujevac,
  26. Nis,
  27. Novi Sad,
  28. Palma de Mallorca, Islas Baleares
  29. Kaohsiung,
  30. Adana,
  31. Ankara,
  32. Ankara,
  33. Antalya,
  34. Gaziantep,
  35. Istanbul,
  36. Izmir,
  37. Izmir,
  38. Kayseri,
  39. Samsun,
  40. Trabzon,
Male
12 Years+
years
MULTIPLE SITES
Hemophilia A, Hemophilia BUnderstanding Hemophilia A and B Drug Dosage Administration Patterns
NCT03248141
  1. Gainesville, Florida
  2. Las Vegas, Nevada
  3. Fort Worth, Texas
ALL GENDERS
0+
years
MULTIPLE SITES
Hemophilia A, Hemophilia BStudy Evaluating Approach to Treatment of Haemophilia A and B in Spain
NCT00581438
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Evaluating Approach to Treatment of Haemophilia A and B in Spain
Official Title Actual Approach to Treatment of Haemophilia A and B in Spain
Brief Summary Analyze the clinical and therapeutic approach to treatment of haemophilia A and B in habitual clinical practice conditions in Spain.
Detailed Description

Analyze the clinical and therapeutic approach to treatment of haemophilia A and B in habitual clinical practice conditions in Spain during the first 3 years since diagnosis.

Assess haemophilia A or B patient profile, study different kinds of hanitual clinical treatment of haemophilia A and B patients, and estimate the kind of treatment and dosage units used per year in patients under habitual clinical practice conditions.

Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population People known to have Haemophilia A or B
Condition
  • Hemophilia A
  • Hemophilia B
Intervention Not Provided
Study Groups/Cohorts 1
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: December 26, 2007)
52
Original Actual Enrollment Same as current
Actual Study Completion Date December 2007
Actual Primary Completion Date December 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Haemophilia A or B patients of any age
  • Written informed consent
Sex/Gender
Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT00581438
Other Study ID Numbers 3082A-102378
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date December 2007